Novelix Pharmaceuticals limited
(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 11th November, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub: Unaudited Standalone Financial Results for the quarter and half year ended 30th September, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ref: Scrip Code: 536565
Scrip Id: NOVELIX

Respected Sir/ Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 11th November, 2026 have considered and approved, the unaudited standalone Financial Results of the company for the quarter and half year ended on 30th September, 2026 along with the limited review report of the auditors thereon.

The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 05:43 p.m. (IST).

The aforesaid information is also available on the website of the Company www.novelixpharma.com We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

For Novelix Pharmaceuticals Limited

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

GNANA PRAKASH GATTU
(Whole-time director)
DIN: 00517921

CVS Balachandra Rao & Co.,
Chartered Accountants

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Novelix Pharmaceuticals Limited

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Novelix Pharmaceuticals Limited** for the quarter and half year ended on 30th September, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the "Listing Regulations').

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CVS Balachandra Rao & Co.,
Chartered Accountants
ICAI Firm Regd No: 007507S

CVS Balachandra Rao
Partner
Membership Number:204580
Place: Hyderabad
UDIN: 26204580HJUWLF3560
Date: 11/11/2026

D.No:3-6-108/1, Flat No:203, Sanatana Eternal, Street No:19, Himayat Nagar, Hyderabad - 500 029. Telangana.
Mobile : 9849035315, 9010624455
Email : cacvsbala@gmail.com, cvsbala67@gmail.com, Website : www.cabrc.in
Branch Office : D.No. 11-33-7B, 2nd Floor, Tatakulavari Street. Samarang Chowk. Vijayawada - 520 001. A.P.

Novelix Pharmaceuticals limited
(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2026

Rs. (In Lakhs) except EPS

Sr. No	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in previous year	6 Months ended	Corresponding 6 Months ended in previous year	Year ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue**						
	a) Income from Operations (Net)	4,473.12	3,691.39	3,635.89	8,164.51	5,871.01	13,230.62
	b) Other Income	-	0.12	3.25	0.12	3.25	3.26
	Total income (a + b)	**4,473.12**	**3,691.51**	**3,639.14**	**8,164.62**	**5,874.26**	**13,233.88**
2	**Expenses**						
	a) Cost of material consumed	-	-	-	-	-	-
	b) Excise duty	-	-	-	-	-	-
	(c) Purchase of stock-in-trade	4,594.11	3,193.39	3,668.48	7,787.50	5,917.98	14,030.37
	(d) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-376.84	292.95	-149.67	-83.89	-221.32	(1,358.89)
	(e) Employee benefits expense	18.77	19.66	14.18	38.43	30.63	71.83
	(f) Finance cost	12.98	11.54	-	24.52	-	-
	(g) Depreciation and amortization expense	12.85	7.00	1.38	19.85	2.48	10.11
	(h) Other expenses	24.63	55.44	32.89	80.07	55.65	140.03
	Total Expenses	**4,286.50**	**3,579.98**	**3,567.25**	**7,866.48**	**5,785.42**	**12,893.45**
3	Profit and (Loss) before exceptional items and tax (3-4)	186.62	111.53	71.89	298.15	88.84	340.43
4	Exceptional Items	-	-	-	-	-	-
5	**Profit and (Loss) after exceptional items but before Tax (5+6)**	**186.62**	**111.53**	**71.89**	**298.15**	**88.84**	**340.43**
6	**Tax Expenses**						
	(a) Current Tax	39.30	25.64	18.03	64.94	21.57	83.02
	(b) Deferred Tax	-9.00	-32.00	0.54	(41.00)	3.24	1.75
	Total Tax Expenses	**30.30**	**(6.36)**	**18.58**	**23.94**	**24.81**	**84.78**
7	**Net Profit/ (Loss) for the Period (7-8)**	**156.32**	**117.89**	**53.31**	**274.21**	**64.03**	**255.66**

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

Novelix Pharmaceuticals limited
(Formerly Known as TRIMURTHI LIMITED)
H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com

8	**Other Comprehensive Income/(Loss)**						
	A) (i) Items that will not be reclassified to Profit & Loss	-	-	-	-	-	-
	(ii)Income tax relating to items that will not be reclassified to profit & loss	-	-	-	-	-	-
	B) (i) Items that will be reclassified to Profit & Loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit & loss	-	-	-	-	-	-
9	**Total Comprehensive Income/(Loss) (9+10)**	**156.32**	**117.89**	**53.31**	**274.21**	**64.03**	**255.66**
10	**Paid up equity share capital (Face Value: Rs. 10 per share)**	2,847.00	2,389.50	1,448.00	2,847.00	1,448.00	1,993.50
12	**Earnings per equity share (of Rs.10/-each) (Not Annualised)**						
	a) Basic	0.57	0.49	0.37	0.96	0.44	1.21
	b) Diluted	0.57	0.49	0.49	0.96	0.58	1.75

NOTES:

1	The above Unaudited Financial Results of the company for the quarter ended September 30th 2026 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 11 November, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://novelixpharma.com/
7	The company has no Subsidiary, Associate or Joint Venture company(ies), as on September 30, 2026

By the order of the Board
For Novelix Pharmaceuticals Limited

Date: 11/11/2026
Place: Hyderabad

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30,2026

(Rs. In Lakhs.)

	PARTICULARS	As at 30th September 2026 (Unaudited)	As at 31st March 2026 (Audited)
	ASSETS		
1	**Non - current assets**		
(a)	Property, plant and equipment	296.01	152.18
(b)	Capital work in progress		
(c)	Right to use assets	18.81	--
(d)	Intangible assets	404.00	192.00
(e)	Financial assets		
	(i) Investments	4.32	4.32
	(ii) Loans		
	(iii) Other financial assets		
(f)	Deferred tax Assets (Net)	43.71	2.71
(g)	Other non-current assets		
	Total non-currrent assets	**766.85**	**351.20**
2	**Current assets**		
(a)	Inventories	1,527.11	1,443.22
(b)	**Financial assets**		
	(i) Investments		
	(ii) Trade receivables	10,574.03	5,896.15
	(iii) Cash and cash equivalents	321.45	295.86
	(iv) Other balances with banks		
	(v) Loans	863.06	983.08
	(vi) Other financial assets		
(c)	Other Current assests	279.24	272.81
	Total current assets	**13,564.89**	**8,891.12**
	TOTAL ASSETS	**14,331.74**	**9,242.32**
	EQUITY AND LIABILITIES		
1	**Equity**		
(a)	Share capital	2,847.00	2,108.50
(b)	Other equity	3,687.79	2,540.34
	Total Equity	**6,534.79**	**4,648.84**
2	**Non-current liabilities**		
(a)	Financial liabilities		
	(i) Long-term borrowings	652.62	432.19
	(ii) Deferred tax liabilities (net)	-	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other non-current liabilities	-	-
	Total non-current liabilities	**652.62**	**432.19**
3	**Current liabilities**		
(a)	Financial liabilities		
	(i) Borrowings		
	(ii) Trade payables	6,930.05	4,025.37

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

	(iii) Other financial liabilities	5.44	-
(b)	Provisions	208.17	135.25
(c)	Other current Liabilities	0.67	0.68
	Total current liabilities	**7,144.33**	**4,161.30**
	Total Liabilities	**7,796.94**	**4,593.48**
	TOTAL EQUITY AND LIABILITIES	**14,331.74**	**9,242.32**

By the order of the Board
For Novelix Pharmaceuticals Limited

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

Date: 11/11/2026
Place: Hyderabad

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER 2026

(Rs. In Lakhs.)

Particulars		As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
A. Cash Flow from Operating Activities:			
Net Profit before Tax and Extraordinary Items		298.15	340.43
Adjustments for:		-	-
Depreciation		19.85	10.11
Interest & Other Income		(0.12)	(3.26)
Loss on Sale of Fixed Assets		-	-
Loss on Sale of Investments & Property		-	-
Profit on sale of mutual funds		-	-
Operating profit before Working Capital Changes	1	**317.88**	**347.28**
Adjustments for:			
(Increase) / Decrease in Trade Receivables		(4,557.86)	(4,363.24)
(Increase) / Decrease in Inventories		(83.89)	(1,358.89)
Increase / (Decrease) in Trade Payables		2,904.68	3,105.25
Increase / (Decrease) in Other Current Liabilities		(13.36)	9.33
Short-Term Provisions		66.05	21.36
Cash generated from Operations	2	(1,684.38)	(2,586.19)
Cash flow before Extraordinary Items	(1-2) =3	**(1,366.50)**	**(2,238.91)**
(Increase) / Decrease Extraordinary Items and Tax		-	-
Net Cash used for Operating activities	4	**(1,366.50)**	**(2,238.91)**
B. Cash Flow from Investing Activities:			
Purchase of Fixed Assets		(355.83)	(325.60)
Sale of Fixed Assets			
Capital Work in progress			
Sale of Investments		-	-
Increase / (Decrease) in Security Deposits - Canara		58.79	150.00
Interest & Other Income		0.12	3.26
Net Cash flow from Investing activities	5	**(296.93)**	**(172.34)**
C. Cash Flow from Financing Activities:			
Increase in Share Capital		738.50	1,113.50
Increase in Share Premium		873.25	1,525.75
Increase / Decrease in Long Term Borrowings		77.27	-
Share Issue and Preliminary Expenses		-	-
Warrents Issued		-	-
Net Cash flow from Financing activities	6	**1,689.02**	**2,639.25**
Net Increase in Cash and Cash Equivalents (A+B+C)	(4+5+6) = 7	**25.59**	**228.00**
Cash and Cash Equivalents as at (Opening Balance)		295.86	67.86
Cash and Cash Equivalents as at (Closing Balance)		321.45	295.86

By the order of the Board
For Novelix Pharmaceuticals Limited

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

Date: 11/11/2026
Place: Hyderabad